Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 5/20 | 0.44 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.38 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.38 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060390 | 0.81 | VCAM1 (0.46) | VCAM1ALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL29546613 | 0.78 | VCAM1 (0.44) | VCAM1ESPL1ALDH1A1HIF1ATDP1 | |
| SCHEMBL29671003 | 0.78 | TSHR (0.42) | VCAM1ALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL28980003 | 0.78 | VCAM1 (0.39) | VCAM1ALDH1A1HIF1ATDP1TSHR | |
| SCHEMBL624089 | 0.78 | TSHR (0.42) | VCAM1ALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL1338960 | 0.78 | VCAM1 (0.44) | VCAM1ESPL1ALDH1A1HIF1ATDP1 | |
| SCHEMBL5258907 | 0.78 | ESPL1 (0.47) | VCAM1ESPL1ALDH1A1HIF1ATDP1 | |
| SCHEMBL3064995 | 0.75 | VCAM1 (0.34) | VCAM1ALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL693936 | 0.74 | MAPT (0.40) | VCAM1ALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL18322039 | 0.74 | HCAR3 (0.43) | VCAM1ALDH1A1TDP1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637754-A2 | SELECTIVE BET INHIBITORS AND USES THEREOF | Tay Therapeutics Limited (GB) | 2025-10-29 | — | — | EP | disclosed |
| US-12384777-B2 | Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts | Tay Therapeutics Limited (GB) | 2025-08-12 | — | — | US | disclosed |
| EP-4219460-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC., | 2025-01-09 | — | — | US | disclosed |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240308998-A1 | PYRROLOPYRIDONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Tay Therapeutics Limited (GB) | 2024-09-19 | — | — | US | disclosed |
| WO-2024138201-A2 | SELECTIVE BET INHIBITORS AND USES THEREOF | Tay Therapeutics Limited (GB) | 2024-06-27 | — | — | WO | disclosed |
| US-20240190865-A1 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| EP-4363417-A1 | PYRROLOPYRIDONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Tay Therapeutics Limited (GB) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024081653-A2 | METHODS OF LOWERING MIRO2 TO TREAT NEURODEGENERATIVE DISEASES | ACUREX BIOSCIENCES CORPORATION (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20180169110-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| WO-2018104766-A1 | 3-(2,3-DIHYDRO-1H-INDEN-5-YL)PROPANOIC ACID DERIVATIVES AND THEIR USE AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-14 | — | — | WO | disclosed |
| EP-3307729-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016203401-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2547338-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| US-6960568-B2 | Nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050239726-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY (US) | 2005-10-27 | — | — | US | disclosed |
| US-20040116362-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239726-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | ADAR, DCTD, ADA | VCAM1 4617/4885ESPL1 4522/4885ALDH1A1 1064/4885 |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | VCAM1 3362/4885ESPL1 4850/4885ALDH1A1 4161/4885 |
| US-20240190865-A1 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | CACNA1G, CACNA1H, CACNB2 | VCAM1 555/4885ESPL1 2120/4885ALDH1A1 4605/4885 |
| US-20240308998-A1 | PYRROLOPYRIDONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | TP53, PYCR1, TPMT | VCAM1 2502/4885ESPL1 4707/4885ALDH1A1 701/4885 |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | VCAM1 1947/4885ESPL1 3012/4885ALDH1A1 4148/4885 |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | VCAM1 1947/4885ESPL1 3012/4885ALDH1A1 4148/4885 |
| US-20180169110-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | VCAM1 2906/4885ESPL1 4418/4885ALDH1A1 621/4885 |
| US-12384777-B2 | Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts | TPMT, IL5, P2RY6 | VCAM1 1497/4885ESPL1 4621/4885ALDH1A1 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.